Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of BAT1006 plus trastuzumab and chemotherapy in previously ADC-treated HER2-positive unresectable or metastatic breast cancer
CTR20251389Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT1006 in breast cancer, sponsored by Bio-Thera Solutions, Ltd.. Started Aug 2025; status: active.
02
Drugs
BAT1006
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251389.